# Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

> **NCT06414954** · PHASE2 · RECRUITING · sponsor: **NMD Pharma A/S** · enrollment: 84 (estimated)

## Conditions studied

- Myasthenia Gravis
- Myasthenia Gravis, MuSK

## Interventions

- **DRUG:** NMD670
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06414954
- **Lead sponsor:** NMD Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-16
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06414954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06414954, "Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06414954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*